Neu Base's average rating is Buy from 5 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Neu Base market sentiment investors' perception of the future value of Neu Base. Let us look at a few aspects of Neu Base technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of NeuBase Therapeutics. In general, sophisticated investors focus on analyzing NeuBase Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build NeuBase Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of NeuBase Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for NeuBase Therapeutics, many experienced traders also check how macroeconomic factors affect NeuBase Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of NeuBase Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as NeuBase Therapeutics. Your research has to be compared to or analyzed against NeuBase Therapeutics' peers to derive any actionable benefits. When done correctly, NeuBase Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in NeuBase Therapeutics.
Watch out for price decline
Please consider monitoring NeuBase Therapeutics on a daily basis if you are holding a position in it. NeuBase Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as NeuBase Therapeutics stock to be traded above the $1 level to remain listed. If NeuBase Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does NeuBase Stands against Peers?
Analyzing NeuBase Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to NeuBase Therapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
NeuBase Therapeutics Competition DetailsNeuBase Therapeutics Gross Profit
NeuBase Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing NeuBase Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show NeuBase Therapeutics Gross Profit growth over the last 10 years. Please check NeuBase Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at Neu Base Mean Deviation
Neu Base Therapeutics has current Mean Deviation of 3.11. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.
Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.
Mean Deviation | = | SUM(RET DEV) N |
| = | 3.11 |
| SUM | = | Summation notation |
| RET DEV | = | Sum of return deviations of Neu Base |
| N | = | Number of calculation points for selected time horizon |
Let's now compare Neu Base Mean Deviation to its closest peers:
| NBSE | 3.11168317493113 |
| DNLI | 3.57 |
| DVAX | 3.67 |
| DYAI | 2.32 |
| EQ | 5.31 |
Another 3 percent surge for Neu Base
Mean deviation is down to 3.11. It may indicate a possible volatility dip. As of the 23rd of January, Neu Base secures the Downside Deviation of 3.0,
risk adjusted performance of 0.0211, and Mean Deviation of 3.11. In connection with
fundamental indicators, the
technical analysis model lets you check existing technical drivers of Neu Base Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed nineteen
technical drivers for Neu Base, which can be compared to its peers in the industry. Please verify
Neu Base Therapeutics jensen alpha,
potential upside, as well as the
relationship between the Potential Upside and
skewness to decide if Neu Base Therapeutics is priced some-what accurately, providing market reflects its recent price of 10.08 per share. Given that Neu Base Therapeutics has
jensen alpha of
(0.00476), we recommend you to check Neu Base's last-minute market performance to make sure the company can sustain itself at a future point.
The Current Takeaway on Neu Base Investment
Although few other entities under the biotechnology industry are still a bit expensive, Neu Base may offer a potential longer-term growth to shareholders. To conclude, as of the 23rd of January 2021, we believe that Neu Base is currently
undervalued with
below average probability of distress in the next two years. However, our primary 30 days 'Buy-Sell' recommendation on the firm is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NeuBase Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com